Clinical Trial

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Name: A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy — clinical trial record (NCT07096843)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PrisMN

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN

Protocol Amendment History 1 change

notable Trial sites expanded: 33 -> 45 locations 2026-05-01

Trial Details

NCT Number	NCT07096843
Lead Sponsor	Climb Bio, Inc.
Conditions	Primary Membranous Nephropathy
Enrollment	45 participants
Start Date	2025-08-25
Primary Completion	2027-10 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-16